Authors declare that they have no competing interests. Received: 11 October 2010 Accepted
Authors declare that they have no competing interests. Received: 11 October 2010 Accepted: 21 May 2011 Published: 21 May 2011 References 1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298-302. 2. Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-15. 3. Chambon P: Adecade of molecular biology of retinoic acid receptors. FASEB J 1996, 10:940-54. 4. Lin RJ, Sternsdorf T, Tini M, Evans RM: Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001, 20:7204-15. 5. Marumoto T, Zhang D, Saya H: Aurora-A: a guardian of poles. Nat Rev Cancer 2005, 5:42-50. 6. Meraldi P, Honda R, Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004, 14:29-36. 7. Liu Q, Ruderman JV: Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci USA 2006, 103:5811-6. 8. Macarulla T, Ramos FJ, Tabernero J: Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008, 3:114-22. 9. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM: Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006, 66:4996-5002. 10. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003, 9:991-7. 11. Kaestner P, Stolz A, Bastians H: Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009, 8:2046-56. 12. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y: Centrosomal kinase AIK1 is overexpressed in invasive PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28878015 ductal carcinoma of the breast. Cancer Res 1999, 59:2041-4. 13. Ulisse S, Baldini E, Toller M, Delcros JG, Gu o A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D’Armiento M, ArlotBonnemains Y: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Ann Surg Oncol 2007, 14:719-29. 14. Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL: Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009, 31:625-34. 15. Siu LL: Promising new targeted agents in head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:59-60. 16. Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q: Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis JC-1 supplier inAurora-A-high acute myeloid leukemia. Blood 2008, 111:2854-65. 17. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A: Targeting aurora kinases as therapy in multiple myeloma. Blood 2007, 109:3915-21. 18. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ: MK0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-2. 19. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL: Sequential ABL kinase inhibitor therapy selects for co.